TriSalus Life Sciences, Inc. (TLSI)
NASDAQ: TLSI · Real-Time Price · USD
7.06
+0.36 (5.37%)
At close: Dec 5, 2025, 4:00 PM EST
7.20
+0.14 (1.98%)
After-hours: Dec 5, 2025, 6:57 PM EST
TriSalus Life Sciences Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for TriSalus Life Sciences stock have an average target of 10.67, with a low estimate of 10 and a high estimate of 11. The average target predicts an increase of 51.13% from the current stock price of 7.06.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 28, 2025.
Analyst Ratings
The average analyst rating for TriSalus Life Sciences stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 2 |
| Buy | 3 | 3 | 3 | 3 | 3 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $11 | Strong Buy | Maintains | $11 | +55.81% | Mar 28, 2025 |
| Roth MKM | Roth MKM | Strong Buy Reiterates $11 | Strong Buy | Reiterates | $11 | +55.81% | Jan 24, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates $10 | Buy | Initiates | $10 | +41.64% | Dec 17, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $12 → $11 | Strong Buy | Maintains | $12 → $11 | +55.81% | Nov 15, 2024 |
| Roth MKM | Roth MKM | Strong Buy Initiates $11 | Strong Buy | Initiates | $11 | +55.81% | Nov 11, 2024 |
Financial Forecast
Revenue This Year
45.64M
from 29.43M
Increased by 55.06%
Revenue Next Year
66.65M
from 45.64M
Increased by 46.04%
EPS This Year
-1.61
from -1.31
EPS Next Year
-0.22
from -1.61
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 47.6M | 75.1M | ||||
| Avg | 45.6M | 66.6M | ||||
| Low | 43.1M | 60.4M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 61.6% | 64.6% | ||||
| Avg | 55.1% | 46.0% | ||||
| Low | 46.5% | 32.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -0.89 | -0.04 | |
| Avg | -1.61 | -0.22 | |
| Low | -1.75 | -0.54 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.